GE HealthCare teams with Mayo Clinic for theranostics trial
GE HealthCare is partnering with a leading healthcare organization to advance research into personalized radioligand therapy for patients with advanced prostate cancer.
The health tech giant announced its collaboration with Mayo Clinic on Wednesday, highlighting the duo's ongoing commitment to research since the 2023 Strategic Radiology Research Alliance was established. The MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) will focus on the use of theranostics in the treatment of prostate cancer.
Most standard radioligand therapy regimens involve a preset number of treatment cycles. However, patients’ specific needs typically differ, and what works for one might not for the next. The goal of MI-BET is to develop strategies that combine imaging- and biomarker-informed insights to personalize care to patients' needs.
GE HealthCare's StarGuide SPECT/CT technology will be used in conjunction with MIM Software's MIM LesionID Pro by researchers involved in the trial. The combo will help give them an idea of how patients are responding to treatment and could potentially pave the way toward establishing predictive markers. This would enable providers to adapt treatment accordingly at a much earlier time than current protocols allow.
"Theranostics, and studies such as MI-BET, give us an important opportunity to rethink how and when we treat cancer," Geoffrey Johnson, MD, PhD, chair of the Radiopharmaceutical Trial Team at Mayo Clinic's Comprehensive Cancer Center, said in the announcement. "By evaluating response earlier in their treatment, we can generate data to drive approaches that could help reduce unnecessary therapy while expanding access to care for wider populations."
"Making theranostics truly adaptive and personalized requires strong clinical evidence and a deeper understanding of how patients respond to therapy," added Sergio Calvo, global general manager of theranostics at GE HealthCare.
Read more about the MI-BET study here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.